Project Grant R01CA290740

Award Date 8/1/24
Completion Date 7/31/29
Dollars Obligated $1M
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $119,059 to Harvard University to conduct research using base editing techniques to elucidate the role of the RAF kinase in KRAS-driven lung cancer. The goal is to better understand RAF kinase function and regulation, including the relative activity of different RAF homo- and hetero-dimers, in order to inform future cancer therapeutic development targeting the RAF signaling pathway. The...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $143,788 to the Broad Institute, Inc. to investigate genetic dependencies in KIAA1549-BRAF rearranged pediatric low-grade gliomas. The key objectives are to: Test the hypothesis that protein O-mannosyltransferase (POMT) enzymatic activity is necessary for the survival of KIAA1549:BRAF rearranged pediatric low-grade glioma cells. Evaluate whether O-mannosylation of the KIAA1549:BRAF...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,827 to New York University School of Medicine to conduct research aimed at enhancing KRAS inhibitor therapy for cancer. The key objectives are to: 1) Evaluate four serine/threonine kinase family members as synthetic lethal targets and clarify the mechanistic basis for this synthetic lethality, and 2) Use CRISPR/Cas9 "mini-libraries" to define the synthetic...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) is providing $111,502.00 to The Ohio State University to support research on the biochemical properties and implications of NRAS mutant-specific BRAF interactions in melanoma. The goal is to elucidate the structural determinants and signaling mechanisms that drive the selectivity of specific NRAS mutations in melanoma development, which could help identify novel therapeutic approaches....
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $147,486 to Carnegie Mellon University to develop novel computational methods for predicting kinase inhibitor off-target activity and optimizing multi-target binding during early-stage drug discovery. The key products and services to be delivered include: Novel methods to reduce the computational expense of alchemical relative binding free energy (RBFE) simulations while maintaining...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Assayquant Technologies, Inc. provides $1,093,104 to develop and commercialize a suite of biosensor peptides for the quantitative, high-throughput measurement of oncogenic protein kinases in cell and tissue samples. The key products to be developed and validated under this 2-year award include: Lysate-compatible sensor peptides for measuring activity of mitogen-activated protein kinases (MAPKs)...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $269,280 to Cold Spring Harbor Laboratory to conduct research on a novel targeted approach for treating K-RAS(G12C) mutation-driven cancers. The research aims to develop prodrug molecules that can selectively degrade the K-RAS(G12C) oncogenic protein while simultaneously releasing cytotoxic natural products to target multiple cancer pathways. Key objectives include determining the...
The National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) federal grant program, awarded a $352,712 Project Grant to The Research Foundation for the State University of New York (Stony Brook University) to define selectivity profiles of clinically approved kinase inhibitors (KIs) against clinically observed MET mutants and calculate optimal KI combinations to maximize selectivity and reduce resistance. The goal is to provide an actionable roadmap for MET...
The National Cancer Institute (NCI) awarded a $652,799 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Fred Hutchinson Cancer Center in Seattle, WA. The grant will fund a 5-year research project to investigate the mechanistic details of "MAPK-driven kinetochore stress" (MASKS) in cancer, particularly glioblastoma. The research aims to reveal how oncogenic signaling via the RAS-RAF-MEK-ERK pathway disrupts kinetochore function, leading to chromosome...
This federal Project Grant award for $716,314.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop novel therapeutics targeting FGFR2 alterations in gastroesophageal adenocarcinoma (GEA). The key products and services to be delivered include: Utilizing novel immune-competent mouse models of FGFR2-altered GEA to develop and test highly efficacious FGFR2 biparatopic antibodies (BIPABs) and FGFR2-targeted antibody-drug conjugates (ADCs), alone or in...

CHEMICAL BIOLOGICAL ANALYSIS OF RAF KINASES - ABSTRACT THE SERINE/THREONINE RAF KINASES FUNCTION AS DOWNSTREAM MODULATORS OF RAS GTPASE-DRIVEN SIGNALING AND ARE KEY DRIVERS OF MANY ONCOGENIC SIGNALING NETWORKS. DESPITE EXTENSIVE EFFORTS TO CHARACTERIZE THE MOLECULAR FUNCTIONS OF RAF KINASES AND TO DEVELOP PHARMACOLOGICAL MODULATORS AS CANCER THERAPIES, MANY ASPECTS OF RAF KINASE REGULATION AND INTRACELLULAR FUNCTION ARE NOT WELL UNDERSTOOD. RECENT WORK SUGGESTS THAT THE INTERPLAY OF DIFFERENT RAF ISOFORMS (A/B/C-R RAF) CAN HAVE A PROFOUND EFFECT ON DOWNSTREAM SIGNALING AND MAY BE A MAJOR DETERMINANT IN THE ABILITY TO PHARMACOLOGICALLY TARGET CANCERS THAT ARE DRIVEN BY MUTANT RAS AND RAF. HERE, WE PROPOSE A SYSTEMATIC BIOCHEMICAL ANALYSIS OF RAF REGULATION, INTRACELLULAR FUNCTION, AND PHARMACOLOGY. LEVERAGING A SUITE OF MOLECULAR TOOLS FOR DISSECTING THE "DRUGGABILITY" OF RAF ISOFORMS, WE WILL DEFINE PATHWAYS THAT MAKE RAF KINASES SENSITIVE OR RESISTANT TO SPECIFIC CLASSES OF ATP-COMPETITIVE INHIBITORS AND CO-INHIBITION STRATEGIES. IN ADDITION, BY APPLYING A NEW RNA BARCODING METHODOLOGY THAT WE'VE DEVELOPED, WE WILL PERFORM DEEP MUTATIONAL SCANS OF THE STRUCTURE, FUNCTION, AND PHARMACOLOGY OF RAF ISOFORMS. FURTHERMORE, WE WILL SYSTEMATICALLY ANALYZE HOW UPSTREAM AND DOWNSTREAM MODULATORS OF RAF KINASE SIGNALING AFFECT THE ACTIVITY AND INTRACELLULAR INTERACTIONS OF RAF KINASES. TOGETHER, THESE STUDIES WILL PROVIDE A MORE COMPLETE PICTURE OF RAF KINASE REGULATION, INTRACELLULAR FUNCTION, AND MAY FACILITATE MORE EFFECTIVE THERAPEUTIC TARGETING OF RAS- AND RAF- DRIVEN CANCERS.

Posted 7/23/24